DEM Biopharma is at the forefront of developing innovative immunotherapeutics that harness the innate immune system to combat cancer. The company focuses on activating macrophages and other myeloid effector cells to target and eliminate tumors by identifying and manipulating specific signals on cancer cells known as "don't eat me" (DEM) and "eat me" (EM) signals. Their proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) employs inter-cellular CRISPR screening to systematically explore these signals in a novel and unbiased manner, utilizing tumor cells and primary macrophages. This approach aims to uncover previously unexplored mechanisms that could enhance the efficacy of cancer treatments.

The expertise of DEM Biopharma's team is a significant asset, with key personnel bringing extensive backgrounds in immunology, oncology, and biopharmaceutical development. The leadership includes individuals with notable experience in T cell immune checkpoints and dendritic cell biology, as well as a strong track record in clinical development and biomanufacturing. This combination of advanced technologies and seasoned professionals positions DEM Biopharma to make substantial contributions to the field of cancer immunotherapy, potentially leading to more effective treatment options for patients.

United States

DEM Bio is pioneering the next generation of immunotherapeutics that unleash macrophages and immune phagocytes to eliminate tumors by targeting ‘Don’t eat me’ (DEM) and ‘Eat me’ (EM) signals on cancer cells and macrophages.  Founded by Longwood Fund and is supported by a syndicate of biotech investors and headquartered in Boston, MA.

DEM Biopharma

Company Details